File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

TitleSafety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
Authors
KeywordsBNT162b2
CoronaVac
COVID-19
inborn errors of immunity
vaccine
Issue Date20-Sep-2022
PublisherFrontiers Media
Citation
Frontiers in Immunology, 2022, v. 13 How to Cite?
Abstract

Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.


Persistent Identifierhttp://hdl.handle.net/10722/329087
ISSN
2023 Impact Factor: 5.7
2023 SCImago Journal Rankings: 1.868
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, D-
dc.contributor.authorMu, XF-
dc.contributor.authorDuque, JSR-
dc.contributor.authorCheng, SMS-
dc.contributor.authorWang, MN-
dc.contributor.authorZhang, WY-
dc.contributor.authorZhang, YM-
dc.contributor.authorTam, IYS-
dc.contributor.authorLee, TSS-
dc.contributor.authorLam, JHY-
dc.contributor.authorChan, SM-
dc.contributor.authorCheang, CH-
dc.contributor.authorChung, Y-
dc.contributor.authorWong, HHW-
dc.contributor.authorLee, AMT-
dc.contributor.authorLi, WY-
dc.contributor.authorChaothai, S-
dc.contributor.authorTsang, LCH-
dc.contributor.authorChua, G-
dc.contributor.authorCheong, KN-
dc.contributor.authorAu, EYL-
dc.contributor.authorKwok, JSY-
dc.contributor.authorChan, KW-
dc.contributor.authorChong, PCY-
dc.contributor.authorLee, PPW-
dc.contributor.authorHo, MHK-
dc.contributor.authorLee, TL-
dc.contributor.authorTu, WW-
dc.contributor.authorPeiris, M-
dc.contributor.authorLau, YL-
dc.date.accessioned2023-08-05T07:55:11Z-
dc.date.available2023-08-05T07:55:11Z-
dc.date.issued2022-09-20-
dc.identifier.citationFrontiers in Immunology, 2022, v. 13-
dc.identifier.issn1664-3224-
dc.identifier.urihttp://hdl.handle.net/10722/329087-
dc.description.abstract<p>Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.</p>-
dc.languageeng-
dc.publisherFrontiers Media-
dc.relation.ispartofFrontiers in Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBNT162b2-
dc.subjectCoronaVac-
dc.subjectCOVID-19-
dc.subjectinborn errors of immunity-
dc.subjectvaccine-
dc.titleSafety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity-
dc.typeArticle-
dc.identifier.doi10.3389/fimmu.2022.982155-
dc.identifier.scopuseid_2-s2.0-85139229224-
dc.identifier.volume13-
dc.identifier.eissn1664-3224-
dc.identifier.isiWOS:000868659800001-
dc.identifier.issnl1664-3224-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats